A Comparison of the Weight Loss Effect between a Low-carbohydrate Diet and a Calorie-restricted Diet in Combination with Intragastric Balloon Therapy

Satoshi Maekawa¹, Makoto Niizawa¹ and Masaru Harada²

Abstract:
Objective Intragastric balloon (IGB) therapy is a low-invasion treatment for obesity. Recently, a low-carbohydrate diet has shown effectiveness for encouraging weight loss, but whether or not a low-carbohydrate diet improves the efficacy of IGB therapy remains unclear. Therefore, we examined the effectiveness of a low-carbohydrate diet compared with a calorie-restricted diet in combination with IGB therapy.

Methods A prospective study was conducted on 51 patients who had undergone IGB therapy from October 2012 to December 2017. Overall, 31 of the 51 patients were included in this study (12-month assessment after IGB placement). These 31 cases consisted of 18 IGB plus low-carbohydrate diet and 13 IGB plus calorie-restricted diet. We compared the two groups with respect to body weight loss as outcomes.

Results At 12 months after IGB placement, the body weight was significantly lower than that observed at baseline in both the IGB plus low-carbohydrate diet group (baseline 101.9±25.8 kg, 12 months 88.2±21.9 kg) (p<0.0001) and the IGB plus calorie-restricted diet group (baseline 103.5±17.0 kg, 12 months 89.1±6.2 kg) (p<0.005). The percentage of excess weight loss in the IGB plus low-carbohydrate diet group was slightly higher than that in the IGB plus calorie-restricted diet group, but there was no significant difference between the 2 groups at 12 months after IGB placement (IGB plus low-carbohydrate 49.9±60.0%, IGB plus calorie-restricted diet 33.1±27.0%).

Conclusion Our study demonstrated that both a low-carbohydrate diet and a calorie-restricted diet were effective interventions for weight reduction in combination with IGB therapy.

Key words: obesity, intragastric balloon, low-carbohydrate diet, calorie-restricted diet, body weight rebound

Introduction

Obesity is one of the most important public health issues, and its incidence is increasing worldwide (1). There is a clear association between obesity and several chronic diseases, such as type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, cerebrovascular diseases, sleep apnea, osteoarthritisy and some cancers (2, 3). Overweight and obesity are also related to increased mortality rates (4). Evidence suggests that weight loss in obese adults reduces morbidity and mortality (5).

Conventional treatments, such as diet therapy, regular physical activity and behavioral modification, are important and essential for managing obesity. However, those treatments alone are often ineffective (6). Bariatric surgery is the most effective weight loss intervention, resulting in long-term sustained weight loss (7) and long-term resolution of comorbidities (8). Despite these advantages, bariatric surgery is still extremely invasive and costly and is likely to cause a vast number of complications that can be fatal (9).

Intragastric balloon (IGB) therapy is a less invasive and more cost-effective option for the treatment of obesity than surgery (10-16). The presence of an IGB delays gastric

¹Nagano Matsushiro General Hospital, Japan and ²Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan

Received for publication November 10, 2019; Accepted for publication December 9, 2019
Correspondence to Dr. Satoshi Maekawa, s5083m@hosp.nagano-matsushiro.or.jp
emptying, causing a premature sensation of satiety and resulting in decreased food consumption (10). IGB therapy becomes even more effective in combination with strict diet therapy (11).

In recent years, low-carbohydrate diets have been shown to be effective for weight reduction and have become increasingly popular all over the world (17-22). Since 2008, the American Diabetes Association (ADA) has recognized that a low-carbohydrate diet as well as a calorie-restricted diet are effective interventions for body weight reduction (23). Although a very-low-calorie ketogenic diet was reported to be useful for increasing the efficacy of IGB therapy (11), whether or not a low-carbohydrate diet improves the efficacy of IGB therapy for body weight management remains unclear.

Therefore, we compared the effectiveness of a low-carbohydrate diet with that of a calorie-restricted diet when used in combination with IGB therapy.

Materials and Methods

Study design and subjects

A prospective single-center study was conducted on 51 patients who had undergone IGB therapy between October 2012 and December 2017. We used computer-generated, blocked randomization to allocate participants to either a low-carbohydrate diet or a conventional calorie-restricted diet in combination with IGB therapy. After randomization, 26 participants were assigned to the low-carbohydrate diet group (IGB plus low-carbohydrate diet), and 25 were assigned to the calorie-restricted diet group (IGB plus calorie-restricted diet). The aim of this study was to compare IGB plus a low-carbohydrate diet with IGB plus a calorie-restricted diet with regard to the kinetics of weight loss and metabolic parameters during 12 months of follow-up after IGB placement.

This study was performed in conformity with the Declaration of Helsinki. Written informed consent was obtained from all patients, and the ethics committee of our hospital approved this study.

IGB procedures

The most commonly used IGB worldwide is the Orbera® IGB [Apollo Endosurgery, Austin, USA; formerly Bioenterics® Intragastric Balloon (BIB®)]. The Orbera® IGB was used in all 51 patients of this study. The inclusion criteria were 1) age between 20 and 75 years old; 2) a body mass index (BMI) ≥27 kg/m²; 3) the presence of one or more obesity-related diseases [ORDs; impaired glucose tolerance (type 2 diabetes etc.), dyslipidemia, hypertension, hyperuricemia/gout, coronary artery disease, cerebral infarction, nonalcoholic fatty liver disease, menstrual abnormalities/sterility, respiratory disorders, osteoarthropathy and renal disease]; and 3) failure of previous therapeutic lifestyle modification for at least six months. The exclusion criteria were 1) active peptic ulcer; 2) inflammatory bowel disease; 3) cancer; 4) history of gastrectomy; 5) hiatal hernia (>5 cm in diameter); 6) pregnancy; 7) psychological disorders inadequately controlled by drug treatment; 8) chronic therapy with aspirin, anti-inflammatory agents, anticoagulants or steroids.

The IGB placement was performed under intravenous sedation (midazolam) and was placed through the mouth while observing with nasal endoscopy. The balloon was positioned in the gastric fundus under endoscopic guidance, inflated with saline (400-700 mL of 1,000 mL saline mixed with 10 mL of 1% methylene blue) until the balloon distended to fill the gastric fundus. The filling catheter was then removed, and the procedure was completed. All patients remained in the hospital for at least three days to observe them for complications, such as abdominal pain and vomiting. At six months after the IGB placement, the balloon was removed under endoscopic guidance.

Diet interventions

For the low-carbohydrate diet group (IGB plus low-carbohydrate diet), we set the total carbohydrate intake to be <120 g/day, as proposed by Shai et al. (18). The intakes of total calories, protein and fat were not limited. For the calorie-restricted diet group (IGB plus calorie-restricted diet), the target calorie intake was defined based on the Japan Society for the Study of Obesity recommendations as follows: total calorie intake (kcal) = height(m)×height(m)×22×2. The target intake of specific macronutrients was as follows: carbohydrate, 50-60%; protein, 15-20%; fat, 20-25% (24). Nutrition education in each group was started at the IGB placement and performed on a one-on-one basis every month after IGB placement by physicians and nutritionists.

Follow-up

Subjects in both groups were asked to attend outpatient guidance sessions and were also reviewed by their physicians every month. The body weight, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured, and the BMI and percentage of excess weight loss [%EWL; (weight loss/initial weight - weight at BMI 25)×100] were calculated at 1-month intervals. The body weight (BW) rebound was defined when the value of %EWL (6 months) - %EWL (12 months) was more than 10%. Blood and urine samples were collected, and the fasting plasma glucose (FPG), hemoglobin Alc (HbA1c), fasting plasma insulin (FPI), homeostasis model assessment of insulin resistance (HOMA-IR=FPG×FPI/405), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs) and uric acid (UA) were measured at each monthly visit. The visceral fat area (VFA) and subcutaneous fat area (SFA) were measured on computed tomographic images at IGB placement and at 12 months after IGB placement.

During the study period, we did not change the medica-
tions. The general health of each subject was assessed, and the results of laboratory tests were explained by the physicians, who gave advice to the patients about both diets for 5-10 minutes at every interview. Thereafter, subjects in both groups received 10- to 15-min individual counseling sessions. The study was continued until 12 months after IGB placement (6 months after IGB removal).

**Statistical analyses**

Results are expressed as the mean±standard deviation. Differences between baseline values and those at 12 months after IGB placement were evaluated by the paired t test for continuous variables. Differences between the two groups were assessed by the unpaired t test for continuous variables and by the chi-square test or Fisher’s exact probability test for categorical variables, as the distribution of each variable did not differ significantly between the two groups. In all analyses, p<0.05 was considered significant, and analyses were performed with the JMP (Ver. 13; SAS, Cary, USA) software program.

**Results**

**Patients**

IGB was placed in 51 patients between October 2012 and December 2017. Twenty-six were allocated to the IGB plus low-carbohydrate diet group, and 25 were allocated to the IGB plus calorie-restricted diet group. Of these 51 patients, 3 did not tolerate the IGB within 2 months after IGB placement (cause of intolerance: anorexia=1, vomiting=2), and 17 stopped attending outpatient guidance sessions within 5 months after IGB removal. Ultimately, 31 of the 51 patients were included in this study (12-month assessment).

The breakdown of these 31 was in the IGB plus low-carbohydrate diet and 13 in the IGB plus calorie-restricted diet (Fig. 1). The general characteristics of the enrolled patients in each group are shown in Table 1. There were no statistically significant differences in any of the parameters between the two groups.

**Body weight loss outcomes**

At 12 months after IGB placement, the body weight and BMI were significantly lower than those observed at baseline both in the IGB plus low-carbohydrate diet group (baseline 101.9±25.8 kg, 37.6±7.1 kg/m², 12 months 88.2±21.9 kg, 32.6±6.3 kg/m²) (p<0.0001 and p<0.0001, respectively) and in the IGB plus calorie-restricted diet group (baseline 103.5±17.0 kg, 38.0±6.1 kg/m², 12 months 89.1±6.2 kg, 32.9±3.8 kg/m²) (p<0.005 and p<0.005, respectively). There were no significant differences in the body weight or BMI outcomes between the two groups (Table 2).

The %EWL in the IGB plus low-carbohydrate diet group was slightly higher than that of the IGB plus calorie-restricted diet group throughout this study (Fig. 2), but the difference between the two groups at 12 months after IGB placement was not significant (IGB plus low-carbohydrate 49.9±60.0%, IGB plus calorie-restricted diet 33.1±27.0%) (Table 2). BW rebound was significantly lower in the IGB plus low-carbohydrate diet (3/18, 16.7%) than in the IGB plus calorie-restricted diet (7/13, 53.8%) (p<0.05).

**Metabolic parameter outcomes**

At 12 months after IGB placement, both groups showed a significant improvement in their HOMA-IR, SBP, DBP and VFA values compared with baseline. However, only the IGB plus low-carbohydrate diet group showed a significant improvement in the HbA1c, TGs, HDL-C, SFA and ORD values compared with baseline at 12 months after IGB placement. There were no significant differences in any of metabolic parameter outcomes between the two groups (Table 2).

**Nutrient intake at 12 months after IGB placement**

We examined the average daily nutrient intake of the two groups by an interview at 12 months after IGB placement. Results showed that 72.2% (13/18) of those in the IGB plus low-carbohydrate diet group achieved a total carbohydrate intake of <120 g/day, and 61.5% (8/13) of those in the IGB plus calorie-restricted diet achieved a target total calorie intake ideal body weight×25. Although we did not prescribe calorie restriction to the patients assigned to the IGB plus low-carbohydrate diet, the calorie intake at 12 months was...
### Table 1. Characteristics of the Patients at Baseline.

| Characteristics        | IGB plus low-carbohydrate diet n=18 | IGB plus calorie-restricted diet n=13 | p value |
|------------------------|-------------------------------------|---------------------------------------|---------|
| Age (years)            | 45.6±12.8                           | 46.5±13.8                             | 0.8516  |
| Female sex - no. (%)   | 11 (61.1)                            | 7 (53.8)                              | 0.6977  |
| BH (cm)                | 163.7±8.0                            | 165.2±8.7                             | 0.6322  |
| BW (kg)                | 101.9±25.8                           | 103.5±17.0                            | 0.8461  |
| BMI (kg/m²)            | 37.6±7.1                             | 38.0±6.1                              | 0.8883  |
| FPG (mg/dL)            | 107.6±25.3                           | 103.9±11.4                            | 0.6555  |
| HbA1c (%)              | 6.1±0.7                              | 6.2±0.6                               | 0.7627  |
| HOMA-IR                | 3.7±2.2                              | 3.7±2.5                               | 0.9848  |
| TGs (mg/dL)            | 116.7±54.6                           | 128.9±55.1                            | 0.5659  |
| HDL-C (mg/dL)          | 52.4±11.4                            | 45.3±11.4                             | 0.1110  |
| LDL-C (mg/dL)          | 128.7±25.9                           | 111.1±40.3                            | 0.1556  |
| UA (mg/dL)             | 6.3±1.1                              | 6.3±2.4                               | 0.9325  |
| SBP (mmHg)             | 136.1±15.6                           | 130.9±17.7                            | 0.3996  |
| DBP (mmHg)             | 85.7±16.0                            | 82.8±9.7                              | 0.5669  |
| VFA (cm²)              | 213.0±86.3                           | 249.3±93.6                            | 0.2743  |
| SFA (cm²)              | 426.8±189.1                          | 390.1±185.9                           | 0.5949  |
| IGB volume (mL)        | 644.4±68.4                           | 653.8±66.0                            | 0.7043  |

Values are the means±standard deviation.

IGB: intragastric balloon, BH: body height, BW: body weight, BMI: body mass index, FPG: fasting plasma glucose, HbA1c: hemoglobin A1c, HOMA-IR: homeostasis model assessment of insulin resistance, TGs: triglycerides, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol, UA: uric acid, SBP: systolic blood pressure, DBP: diastolic blood pressure, VFA: visceral fat area, SFA: subcutaneous fat area, ORDs: obesity-related diseases.

### Table 2. Efficacy Outcomes.

| Variable       | IGB plus low-carbohydrate diet | IGB plus calorie-restricted diet | p value*  |
|----------------|--------------------------------|---------------------------------|-----------|
|                | Baseline                        | 12 months                       | Baseline                          | 12 months                       |         |
| BW (kg)        | 101.9±25.8                      | 88.2±21.9                       | 0.0001*                            | 103.5±17.0                      | 89.1±6.2 | 0.0025*              | 0.8862 |
| BMI (kg/m²)    | 37.6±7.1                        | 32.6±6.3                        | <0.0001*                           | 38.0±6.1                        | 32.9±3.8 | 0.0022*              | 0.9130 |
| %EWL (%)       | -                               | 49.9±60.0                       | -                                  | 33.1±27.0                       | -        | 0.3555               |         |
| BW rebound - no. (%) | -                               | 3 (16.7)                        | -                                  | 7 (53.8)                        | -        | 0.0290*              |         |
| FPG (mg/dL)    | 107.6±25.3                      | 100.5±13.2                      | 0.1738                             | 103.9±11.4                      | 101.5±14.6 | 0.6113               | 0.6555 |
| HbA1c (%)      | 6.1±0.7                         | 5.7±0.6                         | 0.0165*                            | 6.2±0.6                         | 5.9±0.5  | 0.0992               | 0.4308 |
| HOMA-IR        | 3.7±2.2                         | 2.6±1.3                         | 0.0323*                            | 3.7±2.5                         | 2.6±2.2  | 0.0378*              | 0.9310 |
| TGs (mg/dL)    | 116.7±54.6                      | 88.1±41.0                       | 0.0029*                            | 128.9±55.1                      | 109.6±53.2 | 0.3876               | 0.2301 |
| HDL-C (mg/dL)  | 52.4±11.4                       | 58.4±14.5                       | 0.0123*                            | 45.3±11.4                       | 48.8±9.8 | 0.2041               | 0.1616 |
| LDL-C (mg/dL)  | 128.7±25.9                      | 128.6±32.2                      | 0.9837                             | 111.1±40.3                      | 116.1±42.4 | 0.3402               | 0.3675 |
| UA (mg/dL)     | 6.3±1.1                         | 5.9±1.2                         | 0.1801                             | 6.3±2.4                         | 6.0±1.7  | 0.5944               | 0.8293 |
| SBP (mmHg)     | 136.1±15.6                      | 125.7±15.6                      | 0.0103*                            | 130.9±17.7                      | 124.1±17.2 | 0.0452*              | 0.7899 |
| DBP (mmHg)     | 85.7±16.0                       | 75.2±11.6                       | 0.0013*                            | 82.8±9.7                        | 72.1±11.8 | 0.0032*              | 0.4642 |
| VFA (cm²)      | 213.0±86.3                      | 141.5±64.6                      | 0.0002*                            | 249.3±93.6                      | 174.3±117.3 | 0.0252*               | 0.3259 |
| SFA (cm²)      | 426.8±189.1                     | 337.7±186.6                     | 0.0094*                            | 390.1±185.9                     | 330.6±191.8 | 0.2090               | 0.9187 |
| ORDs           | 2.9±1.9                         | 2.3±2.1                         | 0.0370*                            | 2.2±1.2                         | 2.0±1.4  | 0.0821               | 0.6221 |

*The results were considered significant at p<0.05 for within-group comparisons.

†The results were considered significant at p<0.05 for between-group comparisons.

Values are the means±standard deviation.

BW: body weight, BMI: body mass index, %EWL: (weight loss/(initial weight-weight at BMI 25))×100. The BW rebound was defined when the value of %EWL (6 months)-%EWL (12 months) was more than 10%. FPG: fasting plasma glucose, HbA1c: hemoglobin A1c, HOMA-IR: homeostasis model assessment of insulin resistance, TGs: triglycerides, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol, UA: uric acid, SBP: systolic blood pressure, DBP: diastolic blood pressure, VFA: visceral fat area, SFA: subcutaneous fat area, ORDs: obesity-related diseases.
similar in both groups (IGB plus low-carbohydrate diet 1,550.0±146.5 kcal, IGB plus calorie-restricted diet 1,523.1±178.7 kcal). The relative nutrient intake of carbohydrates, protein and fat was 26.8±10.4%, 23.6±5.7% and 44.3±5.7% in the IGB plus low-carbohydrate diet group, compared with 52.9±7.0%, 17.3±2.6% and 28.9±6.0%, respectively, in the IGB plus calorie-restricted diet group. The carbohydrate intake was significantly lower in the IGB plus low-carbohydrate diet group than in the IGB plus calorie-restricted diet group (p<0.0001). In contrast, the protein and fat intake were significantly lower in the IGB plus calorie-restricted diet group than in the IGB plus low-carbohydrate diet group (p<0.001 and p<0.0001, respectively) (Table 3).

Table 3. Nutrition Intake at 12 Months.

|                      | IGB plus low-carbohydrate diet | IGB plus calorie-restricted diet | p value* |
|----------------------|--------------------------------|---------------------------------|----------|
| Calorie intake (kcal)| 1,550.0±146.5                  | 1,523.1±178.7                  | 0.6486   |
| Calorie intake/IBW   | 23.2±2.8                       | 22.6±3.8                       | 0.5615   |
| Carbohydrate (g)     | 103.9±42.0                     | 201.2±35.4                     | <0.0001* |
| Protein (g)          | 91.7±25.7                      | 66.2±14.2                      | 0.0009*  |
| Fat (g)              | 76.1±11.1                      | 49.2±13.1                      | <0.0001* |

*The results were considered significant at p<0.05 for between-group comparisons. Values are means±standard deviation. IGB: intragastric balloon, IBW: ideal body weight

Discussion

The efficacy of IGB placement for body weight loss was first reported by Nieben et al. in 1982 (25). Since then, various balloons have been tested, but complications have been relatively frequent. In 1999, a new balloon, the BIB®, which has a spherical shape and increased volume of saline (400-700 ml), was introduced (26, 27). Extensive clinical experience with the BIB® has shown a low complication rate, efficacy in weight loss and improvement of comorbidities (13, 14). In Japan, Ohta first reported the efficacy of IGB placement in 2008 (28). However, experience with IGB placement in Japan has been very limited (28-32). In this study, we performed IGB placement therapy in obese Japanese patients and demonstrated the efficacy of IGB placement in achieving weight loss. Three patients did not tolerate the IGB within two months after its placement, but there were no serious complications.

IGB placement is a temporary six-month treatment for obesity, and the maintenance of weight loss after the removal of the balloon is very important. Diet therapy is the most important factor for maintenance. The efficacy of the IGB therapy was linked both to the balloon itself and to a calorie-restricted diet (12-14, 28, 33-35).
A low-carbohydrate diet has become a popular strategy for achieving weight loss and managing weight in recent years. Many reports from all over the world have found that a low-carbohydrate diet is more effective than a calorie-restricted diet for weight loss (17-22). It was recently reported that a low-carbohydrate diet is useful for promoting weight loss in Japan (36). Although a low-calorie diet and very-low-calorie diet are both reportedly useful for increasing the efficacy of IGB therapy (11), whether or not a low-carbohydrate diet improves the efficacy of IGB therapy for weight management remains unclear. Therefore, we compared the effectiveness of a low-carbohydrate diet and a calorie-restricted diet in combination with IGB therapy.

In the present study, at 12 months after IGB placement, the body weight and BMI were significantly lower than those observed at baseline in both groups. There were no significant differences in the body weight or BMI outcomes between the two groups (Table 2). Our study showed that both a low-carbohydrate diet and a calorie-restricted diet are effective interventions for weight management in combination with IGB therapy.

Although we did not prescribe calorie restriction to the patients assigned to the IGB plus low-carbohydrate diet, the calorie intake at 12 months was similar in both groups (Table 3). The patients in IGB plus low-carbohydrate diet may have quickly felt satiated because they ate protein and fat, such as meat or fish, in place of carbohydrates. In addition, it may be difficult to overeat only side dishes, such as meat or fish. Alternatively, this may have been the result of patients in both groups being able to correct their habit of overeating during the period of IGB insertion.

The %EWL in the IGB plus low-carbohydrate diet group was slightly higher than that in the IGB plus calorie-restricted diet group throughout the 12 months of this study, although there were no significant differences (Fig. 2). The BW rebound was significantly lower in the IGB plus low-carbohydrate diet group than in the IGB plus calorie-restricted diet group (Table 2). This may be because a low-carbohydrate diet can be easily understood and maintained because patients need only focus on reducing carbohydrates, compared with a calorie-restricted diet. The patients in the IGB plus low-carbohydrate diet group were able to limit the amount of staple foods consumed (such as rice, bread, noodles and so on) than that of sugary foods (such as cake, ice cream, juice and so on), as carbohydrate-rich foods. Most patients who experienced BW rebound in both groups failed to adhere to the advised nutrient intake. Our study demonstrated that an IGB plus both a calorie-restricted diet as well as a low-carbohydrate diet were effective interventions for reducing and managing weight.

At 12 months after IGB placement, both groups showed a significant improvement in HOMA-IR, SBP, DBP and VFA values compared with baseline. However, only the IGB plus low-carbohydrate diet group showed a significant improvement in the HbA1c, TGs, HDL-C, SFA and ORD values (Table 2). The low-carbohydrate diet may have had a greater effect than the calorie-restricted diet, as there are some reports in which a low-carbohydrate diet showed a significant improvement in the HbA1c, TGs, HDL-C, SFA and ORD values (18-22, 36). Regardless, IGB therapy plus a low-carbohydrate diet was suggested to be effective for improving obesity comorbidities.

Several limitations associated with the present study warrant mention. First, the number of patients we treated was too small to detect significant differences in the between-group comparison, except for BW rebound. Therefore, a large-scale trial is needed in order to indicate the generality of our findings. Second, this study had a short term. A longer trial on a combination diet with IGB therapy will be necessary. Third, we were unable to assess all patients who participated in this study because many of the patients dropped out before the end of the study period. We need to analyze the reasons for dropout and devise efforts to reduce the dropout rate in the future.

In conclusion, our study demonstrated that a low-carbohydrate diet as well as a calorie-restricted diet were both effective interventions for reducing and managing weight when used in combination with IGB therapy. A large-scale study is necessary to confirm the efficacy of a low-carbohydrate diet in combination with IGB therapy.

The authors state that they have no Conflict of Interest (COI).

References

1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet 384: 766-781, 2014.
2. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 25: 9:88, 2009.
3. Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Maneg Care 22 (Suppl): s176-s185, 2016.
4. Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 388: 776-786, 2016.
5. Kritchevsky SB, Beavers KM, Miller ME, et al. Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials. PLoS One 10: e0121993, 2015.
6. Loveman E, Frampton GK, Shepherd J, et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess 15: 1-182, 2011.
7. Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity. Eur J Endocrinol 158: 135-145, 2008.
8. Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg 24: 437-455, 2014.
9. Goldfeder LB, Ren CJ, Gill JR. Fatal complications of bariatric surgery. Obes Surg 16: 1050-1056, 2006.
10. Stimac D, Majanovc SK, Turk T, et al. Intragastric balloon treatment for obesity: results of a large single center prospective study. Obes Surg 21: 551-555, 2011.
loss by combination of two temporary antiobesity treatments. Obes Surg 28: 3733-3737, 2018.
12. Dastis NS, François E, Deviere J, et al. Intragastric balloon for weight loss: results in 10 individuals followed for at least 2.5 years. Endoscopy 41: 575-580, 2009.
13. Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg 15: 1161-1164, 2005.
14. Sallot JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg 14: 991-998, 2004.
15. Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg 15: 864-870, 2005.
16. Ribeiro DSJ, Procença L, Rodrigues A, et al. Intragastric balloon for obesity treatment: safety, tolerance, and efficacy. GE Port J Gastroenterol 25: 236-242, 2018.
17. Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 297: 969-977, 2007.
18. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 359: 229-241, 2008.
19. Hession M, Rolland C, Kulkarni U, Wise A, Broom J. Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. Obes Rev 10: 36-50, 2009.
20. Santos FL, Esteves SS, da Costa Pereira A, Yancy WS Jr, Nunes JP. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev 13: 1048-1066, 2012.
21. Bazzano LA, Hu T, Reynolds K. Effects of low-carbohydrate and low-fat diets, a randomized trial. Ann Intern Med 161: 309-318, 2014.
22. Sackner-Bernstein J, Kanter D, Kaul S. Dietary intervention for overweight and obese adults: comparison of low-carbohydrate and low-fat diets. a meta-analysis. PLoS One 10: e0139817, 2015.
23. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 31: S61-S78, 2008.
24. Japan Society for the Study of Obesity. Guidelines for the management of obesity disease 2016. Lifescience Publishing, Tokyo, 2016: 38-60 (in Japanese).
25. Nieben OG, Haboe H. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet 1: 198-199, 1982.
26. Galloro G, DePalma GD, Catanzano C, et al. Preliminary endoscopic technical report of a new silicone intragastric balloon in the treatment of morbid obesity. Obes Surg 12: 9: 68-71, 1999.
27. Totte E, Hendrickk L, Pauwels M, et al. Weight reduction by means of intragastric device: experience with the BioEnterics Intragastric Balloon. Obes Surg 11: 519-523, 2001.
28. Ohta M, Kitano S, Kai S, et al. Initial Japanese experience with intragastric balloon placement. Obes Surg 19: 791-795, 2009.
29. Takihata M, Nakamura A, Aoki K, et al. Comparison of intragastric balloon therapy and intensive lifestyle modification therapy with respect to weight reduction and abdominal fat distribution in super-obese Japanese patients. Obes Res Clin Pract 8: e331-e338, 2014.
30. Goto M, Inoue K, Tanaka T, et al. A morbid obese Japanese woman with a body mass index of 83.2 kg/m²: before and after sleeve gastrectomy. Intern Med 51: 969-975, 2012.
31. Sekino Y, Imajo K, Sakai E, et al. Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. Intern Med 50: 2449-2455, 2011.
32. Sekino Y, Iida H, Endo H, et al. Effectiveness of repeated intragastric balloon therapy in a morbidly obese Japanese patient. Intern Med 50: 109-112, 2011.
33. Genco A, Cipriano M, Bacci V, et al. BioEnterics intragastric balloon (BIB): a short term, double-blind, randomized, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes 30: 129-133, 2006.
34. Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics intragastric balloon (BIB). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg 21: 5-9, 2011.
35. Genco A, Balducci S, Bacci V, et al. Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg 18: 989-992, 2008.
36. Maekawa S, Nomura R, Ann Y, Harada M. Comparison of weight loss effect in one year of a low-carbohydrate diet versus an energy-restricted diet (a calorie-restricted diet) in Japanese obese patients. Journal of Japanese Society for the Study of Obesity 23: 36-48, 2017 (in Japanese).

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).